Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inmune Bio Inc (INMB)
NASDAQ:INMB
Holding INMB?
Track your performance easily
INMB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.78 - $14.74
Previous Close$6.13
Volume124.76K
Average Volume (3M)251.00K
Market Cap
$137.91M
Enterprise Value$107.27M
Total Cash (Recent Filing)$33.55M
Total Debt (Recent Filing)$2.91M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Feb 27, 2025EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding22,172,451
10 Day Avg. Volume272,537
30 Day Avg. Volume250,996
Standard Deviation0.27
R-Squared0.13
Alpha0.00902
Financial Highlights & Ratios
Price to Book (P/B)3.52
Price to Sales (P/S)3283.63
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.55K
Enterprise Value/Gross Profit692.09
Enterprise Value/Ebitda-5.63
Forecast
1Y Price Target
$19.83Price Target Upside223.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Inmune Bio News
PremiumCompany Announcements
Inmune Bio Reports Increased Losses Amid Financing Efforts
PremiumPre-Earnings
Inmune Bio (INMB) Q3 Earnings Cheat Sheet
Ownership Overview
20.40% Insiders
4.23% Mutual Funds
0.99% Other Institutional Investors
68.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INMB FAQ
What was Inmune Bio Inc’s price range in the past 12 months?
Inmune Bio Inc lowest stock price was $4.78 and its highest was $14.74 in the past 12 months.
What is Inmune Bio Inc’s market cap?
Currently, no data Available
When is Inmune Bio Inc’s upcoming earnings report date?
Inmune Bio Inc’s upcoming earnings report date is Feb 27, 2025 which is in 110 days.
How were Inmune Bio Inc’s earnings last quarter?
Inmune Bio Inc released its earnings results on Oct 31, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.507 by -$0.093.
Is Inmune Bio Inc overvalued?
According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued.
Does Inmune Bio Inc pay dividends?
Inmune Bio Inc does not currently pay dividends.
What is Inmune Bio Inc’s EPS estimate?
Inmune Bio Inc’s EPS estimate is -$0.55.
How many shares outstanding does Inmune Bio Inc have?
Inmune Bio Inc has 22,172,451 shares outstanding.
What happened to Inmune Bio Inc’s price movement after its last earnings report?
Inmune Bio Inc reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.507. Following the earnings report the stock price went up 3.248%.
Which hedge fund is a major shareholder of Inmune Bio Inc?
Currently, no hedge funds are holding shares in INMB
---
Inmune Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.83 (223.49% Upside)
$19.83 (223.49% Upside)
Blogger Sentiment
Neutral
INMB Sentiment 50%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $199.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.6%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.79%
12-Months-Change
Fundamentals
Return on Equity
-98.97%
Trailing 12-Months
Asset Growth
-15.82%
Trailing 12-Months
Company Description
Inmune Bio Inc
Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
---
INMB Earnings Call
Q3 2024
0:00 / 0:00
---
INMB Stock 12 Month Forecast
Average Price Target
$19.83
▲(223.49% Upside)
Technical Analysis
Adial Pharmaceuticals
―
Brainstorm Cell Therapeutics
―
Clearside Biomedical
―
Cyclerion Therapeutics
―
Best Analysts Covering INMB
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
-4.84%
reiterated a buy rating 4 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -4.84% per trade.
---